Key facts
- Notable investors include Connecticut Innovations, EMBR Capital, SmiLe Incubator.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Apriligen
- ·The full record, as it builds
Funding rounds
No funding rounds for Apriligen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Apriligen
Operator of a biotechnology company intended to develop therapies for illnesses with either no cure or unsatisfactory, ineffective, and harmful standard treatments. The company's process involves extracting red blood cell-generating stem and progenitor cells from a patient, sequencing the target gene in a laboratory, removing the dormant gene from the cells ex-vivo, and replacing it with a functional, nutritive copy of the gene, enabling health researchers to find cures to rare, monogenic pediatric illnesses.
- Sector
- Healthcare
- HQ
- Greenwich, CT, United States
- Founded
- 2020
- Website
- apriligen.com/
- Ownership
- Privately Held (backing)
Apriligen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apriligen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apriligen in its N-PORT filings yet. We sweep new filings monthly.